Head-to-head · free

Regeneron Pharmaceuticals, Inc. vs Senseonics Holdings, Inc.

REGN vs SENS — return on capital, cash generation, margins and balance sheet side by side.

REGN

5 / 6

measures where REGN leads

SENS

1 / 6

measures where SENS leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureREGN · FY2025SENS · FY2025
Revenue$14.3B$35.3M
Net income$4.5B(69.1M)
Revenue growth (yearly, multi-year)-2.8%26.7%
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC9.3%—
Return on equity14.9%—
Gross margin85.4%44.7%
Operating margin25.8%-193.8%
Net debt / EBITDA-0.27x0.07x

Figures are as reported by each company; latest fiscal year shown.

Where Regeneron Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full REGN profile →

Where Senseonics Holdings, Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full SENS profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons